TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 13, 2018, details the results of the annual meeting of stockholders held by TG Therapeutics, Inc. The meeting took place at the offices of Alston & Bird LLP in New York, New York. Stockholders representing 62,395,470 shares (80.33% of the 77,666,112 shares entitled to vote) were present in person or by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Three proposals were presented and approved by the stockholders:
- Proposal 1 (Election of Directors): Seven individuals were elected to the Board of Directors to serve until the 2019 annual meeting. While all were elected, voting support varied significantly among candidates:
| Director | Votes For | Votes Withheld |
|---|---|---|
| Michael S. Weiss | 34,700,747 | 4,776,720 |
| Laurence N. Charney | 25,138,011 | 14,339,456 |
| William J. Kennedy | 25,139,461 | 14,338,006 |
| Mark Schoenebaum, MD | 22,987,997 | 16,489,470 |
| Yann Echelard | 32,433,930 | 7,043,537 |
| Kenneth Hoberman | 32,420,553 | 7,056,914 |
| Daniel Hume | 32,433,698 | 7,043,769 |
- Proposal 2 (Auditor Ratification): CohnReznick LLP was approved as the independent registered public accountant for the fiscal year ending December 31, 2018. Votes cast were 61,581,162 For, 365,659 Against, and 448,649 Abstentions.
- Proposal 3 (Equity Plan Amendment): An amendment to the Amended and Restated 2012 Incentive Plan was approved to increase the number of shares available for issuance by 6,000,000. Votes cast were 33,670,966 For, 5,283,744 Against, and 522,757 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting the mechanics and results of the shareholder vote.
Key Facts for Investor Verification
- Verify the specific terms of the 6,000,000 share increase to the 2012 Incentive Plan to assess potential dilution.
- Note the significant number of votes withheld for directors Laurence N. Charney, William J. Kennedy, and Mark Schoenebaum, MD, which may indicate shareholder dissatisfaction despite their election.
- Confirm the tenure of the newly elected board members, which extends only until the 2019 annual meeting.
- Review the definitive proxy statement dated April 30, 2018, for detailed background on the proposals and director biographies.